Cibalgina Dol: Main Uses and Benefits

The primary role of Cibalgina Dol is to provide symptomatic relief applied across therapeutic domains involving pain, fever, and inflammation. It is intended for the temporary relief of pain and/or inflammation associated with a broad range of conditions. This medication is commonly used to help with challenging symptoms that may become disruptive, such as mild to moderate pain from headache, toothache, and musculoskeletal aches, alongside fever and the discomfort of menstrual cramping.

Its relevance in acute scenarios supports the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort. It is relevant in contexts involving systemic imbalance (like fever) and localized inflammatory or irritative states (like swelling). The medication assists with managing symptom clusters that create noticeable physiological strain.

“It is relevant for easing the overall symptom load by assisting with the reduction of fever and managing accompanying general aches and pains.”

---

Quick Fact: Relief for Episodic Discomfort

Symptom Domain	Common Scenario	Patient Benefit
Pain & Fever	Cold/flu symptoms	Supports the handling of distressing manifestations
Inflammation	Minor injuries, sprains	Assists with maintaining functional stability
Recurrent Pain	Menstrual cramping	Helps ease the overall symptom burden

Regulatory References

1. Therapeutic Goods Administration Monograph on Ibuprofen

Eligibility Map: Who Can and Cannot Use Cibalgina Dol

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adults, adolescents (generally ge 12 years or ge 40 kg), and children (ge 6 years or ge 20 kg for specific oral forms). Use is considered compatible with breastfeeding.

Populations for whom use is contraindicated: Patients with severe cardiac, hepatic, or renal failure, active or recurrent peptic ulcers/GI bleeding, or known hypersensitivity to Ibuprofen or any NSAID, including aspirin-sensitive asthma. Use is prohibited during the third trimester of pregnancy (after 30 weeks gestation) and in the setting of CABG surgery.

Age-related eligibility rules: The elderly are at increased risk of adverse events and must be treated with caution. Use is generally restricted for children under six years of age.

Condition-specific eligibility rules: Patients with mild to moderate organ impairment or a history of cardiovascular disease require conditional use and monitoring. The FDA recommends avoiding use from 20 weeks gestation onward unless essential.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute prohibition for severe organ failure/GI bleeding) and Use with Caution/Restricted (for mild-to-moderate organ impairment/elderly).

Regulatory basis: Summary of Product Characteristics (SmPC) / FDA Prescribing Information.

Eligibility-context constraints (as defined in official documents): Constraints based on organ function, age/weight minimums, and pregnancy trimester.

Resulting Eligibility Structure

Official eligibility statements:

• Contraindicated in the third trimester of pregnancy and in patients with severe cardiac, hepatic, or renal failure.
• Must not be given to patients with a history of recurrent peptic ulcers or NSAID-related allergies.
• Use requires caution in the elderly and patients with mild to moderate organ impairment or cardiovascular disease.

Connection to the overall eligibility profile: Official regulatory documents establish clear boundaries for Cibalgina Dol use by classifying populations into groups that are absolutely prohibited (contraindicated), groups that require strict cautionary conditions, and those for whom use is established based on a patient's organ function, disease history, and physiological state.

Cibalgina Dol (Ibuprofen) exhibits several officially documented interaction patterns with other medicines and products. The regulatory label classifies co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors, as contraindicated due to a significantly increased risk of serious gastrointestinal bleeding and ulceration. Use is also prohibited for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Ibuprofen engages in pharmacodynamic interference with several drug classes. It may attenuate the antiplatelet effect of low-dose Aspirin; regulatory guidance mandates that a 400 mg dose of Ibuprofen be taken at least 8 hours before or 30 minutes after immediate-release Aspirin. Concomitant use with Anticoagulants (such as Warfarin), Oral Corticosteroids, Antiplatelet Agents, and Selective Serotonin Re-uptake Inhibitors (SSRIs) is officially associated with an additive risk of gastrointestinal hemorrhage.

The medicine can also cause altered drug exposure for certain agents. It officially reduces the clearance and increases the plasma concentration of Lithium and Methotrexate by inhibiting their renal elimination. Furthermore, Ibuprofen may reduce the efficacy of Antihypertensive agents and Diuretics, which can also increase the risk of nephrotoxicity, a risk heightened in the elderly or those with existing renal impairment. Consuming alcohol during treatment is officially noted to increase the risk of stomach bleeding.

Inhibition of Inflammatory Signaling (Ibuprofen)

The ibuprofen component works by non-selective, reversible inhibition of Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This interaction interferes with the arachidonic acid metabolic pathway, preventing the conversion of arachidonic acid into prostaglandins—local chemical mediators. Limiting the production of these mediators results in two primary physiological modulations: decreased sensitization of peripheral nociceptors and the lowering of the hypothalamic temperature set-point.

Central Modulation (Caffeine)

Caffeine operates primarily within the central nervous system (CNS) by acting as a non-selective antagonist of adenosine receptors. This mechanistic interference blocks adenosine from reducing neuronal activity, leading to CNS stimulation. This central action contributes to cerebral vasoconstriction and modulates neural signaling dynamics in pathways associated with pain processing, acting by a mechanism distinct from ibuprofen's peripheral effects.

Dual-Action Pathway Convergence

The combined mechanism provides multi-modal pathway modulation by simultaneously addressing the peripheral inflammatory cascade (via enzyme inhibition) and central neural dynamics (via receptor antagonism). This convergence results from both an upstream reduction in the biochemical synthesis of pain-sensitizing mediators and a downstream alteration of central signaling patterns.

Cibalgina Dol, which contains Ibuprofen, is designated for oral administration using dosage forms such as tablets, capsules, or suspensions. Usage is generally guided by the application of the lowest effective dose for the shortest duration necessary to manage symptoms.

---

Standard Dosing Principles

For short-term, acute relief in adults, the standard single dose ranges from 200 mg to 400 mg, with the total daily amount restricted to 1200 mg when used without a prescription. When administered for chronic conditions, such as certain rheumatic diseases, the daily dose may be increased up to 3200 mg, but this amount must be divided and taken across the day. The proper scheduling requires a minimum interval of four to six hours between successive doses.

---

Contextual Instructions

Oral doses may be taken with food or milk. This is provided as a means to mitigate potential gastrointestinal discomfort, without substantially altering the medicine's absorption. For older adults and patients with mild hepatic or renal impairment, it is recommended that the dosage be initiated at the lowest possible effective dose and monitored closely. The duration of use generally does not exceed 10 days for self-managed pain relief. If a dose is missed, the standard practice is to skip the dose if it is near the time of the next scheduled intake, and not to take a double dose.

Cibalgina Dol: Recent Clinical Evidence

Evidence Supporting Acute Pain Relief

The medicine was studied for conditions associated with acute or disruptive episodes, such as short-term headache, dental pain, and musculoskeletal aches. The research evidence includes Randomized Controlled Trials (RCTs) and Systematic Reviews where researchers examined outcomes related to physical discomfort. Studies monitored the change in patient-reported pain intensity scores over defined time intervals.

Findings describe patterns observed in the studies where pain scores changed during the observation period, with data suggesting the existence of an "analgesic ceiling" concept in the observed populations.

Evidence Supporting Fever Reduction and Primary Dysmenorrhea

The medicine was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations of fever in both pediatric cohorts (children aged three months and older) and adults. These studies monitored outcomes related to systemic or functional imbalance, focusing on the time required for temperature to change and the duration of that change. Studies comparing the medicine to other agents reported differences in temperature change measurements at certain early time points. Research exploring combination therapy for fever has limited evidence, and data for very young infants remain insufficient.

The medicine was studied for conditions involving periods of heightened symptoms related to primary dysmenorrhea (menstrual cramping). Researchers monitored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. Research has primarily examined primary dysmenorrhea specifically, and other forms of pelvic pain were not the primary focus of these trials.

The Research Landscape and Remaining Uncertainties

Research generally focuses on short-term or episodic symptom patterns for non-prescription use, meaning that follow-up durations were limited in many trials. This short follow-up provides context for acute episodic symptom patterns. Long-term effects are not fully established as data is largely drawn from studies that involved patients taking higher, prescription-only doses for chronic conditions.

The medicine was evaluated in research that included both adults and certain pediatric cohorts. However, data for certain groups remain insufficient, such as in patients with certain comorbid conditions. It is important to remember that findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. A single dose of ibuprofen administered orally to treat acute postoperative pain in adults (Cochrane Review)
2. Fever in under 5s: assessment and initial management (NICE Guideline NG143)
3. OTC medicine monograph: Ibuprofen for oral use (Therapeutic Goods Administration - TGA)

Common questions about Cibalgina Dol (FAQ)

Q: Is Cibalgina Dol the same as regular ibuprofen?

A: Cibalgina Dol contains the active ingredient ibuprofen. Official regulatory documents indicate that different formulations of ibuprofen, such as those that use a salt form or special coating, can affect how quickly the medicine is absorbed by the body. Therefore, while the core medicine is the same, the specific product may have properties that influence its action time.

Q: Is Cibalgina Dol available without a prescription in most places?

A: According to regulatory guidance, ibuprofen is widely available over-the-counter (OTC) for short-term use. Regulatory documents describe the maximum dose limits for ibuprofen products intended for over-the-counter (OTC) availability. Higher single doses are typically reserved for prescription use.

Q: Is there any difference between Cibalgina Dol and other over-the-counter pain medications?

A: Cibalgina Dol is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID) in regulatory documentation. This classification means it works differently than non-NSAID pain relievers, such as paracetamol (acetaminophen). Because of this difference in how it works, NSAIDs carry specific warnings, such as for the risk of gastrointestinal issues.

Q: Are headaches a potential side effect of Cibalgina Dol?

A: Yes, official documentation notes that headache is listed among the possible adverse reactions associated with ibuprofen use. Official documentation categorizes various effects, although regulatory documents may show variability in the reported frequency.

Q: Are there specific food restrictions while taking Cibalgina Dol?

A: Regulatory guidance permits taking this medicine with food or milk, which is often suggested to help reduce potential stomach upset. No specific food restrictions are typically required. However, official warnings describe that alcohol consumption during treatment is associated with an increased risk of stomach bleeding.

Q: Is Cibalgina Dol suitable for long-term use?

A: Regulatory guidance indicates that use for self-managed pain relief is intended for the shortest duration possible, often with a typical limit of 10 days described in the label. Regulatory warnings note that the risk of serious side effects, particularly affecting the stomach and heart, is known to increase with longer duration of use and higher doses.

Q: Is it common to feel dizzy after taking Cibalgina Dol?

A: Dizziness is listed in the official regulatory labeling as a possible adverse reaction. Official guidance describes that caution is required when driving a motor vehicle or operating machinery if nervous system effects like dizziness are experienced. Alcohol or sedatives may increase this risk.

Q: Why is Cibalgina Dol sometimes described as having a faster onset?

A: Official bioequivalence reviews show that some ibuprofen formulations, often those using a salt form (like sodium) or special release technologies, are designed to be absorbed more quickly. This formulation difference leads to the rapid onset of higher concentrations in the bloodstream compared to standard ibuprofen acid preparations.

Q: What are the most commonly reported side effects in clinical trials for Cibalgina Dol?

A: According to official documentation, the most common side effects reported in clinical trials typically involve gastrointestinal issues. These often include things like abdominal pain, nausea, upset stomach, and gas. The full list of common and uncommon effects is detailed in the complete regulatory product information.

Q: Does taking Cibalgina Dol affect blood pressure?

A: Official regulatory warnings state that NSAIDs, including ibuprofen, are associated with a modest increase in blood pressure. Fluid retention and hypertension (high blood pressure) have been reported, and caution is required, particularly for patients with a history of heart failure or high blood pressure.

Q: Are there different strengths of Cibalgina Dol available?

A: Regulatory documents indicate that ibuprofen is commonly available in various strengths for over-the-counter use, with higher strengths typically being restricted to prescription use. The full range of available product strengths is detailed in the regulatory product information.

Q: Can Cibalgina Dol be taken if I am already taking medication for anxiety?

A: Official safety documents list interactions with certain medications, including Selective Serotonin Re-uptake Inhibitors (SSRIs), a common class of medication used for anxiety and depression. Taking ibuprofen with SSRIs is known to increase the risk of gastrointestinal bleeding. Because of potential interactions with CNS-acting medicines, official information notes that the combined use of these products should be reviewed by a healthcare professional.

Q: How quickly can I expect Cibalgina Dol to start working?

A: Official drug profiles indicate that after taking the medicine by mouth, the effect typically begins within about one hour. Peak concentrations of the medicine in the blood are usually reached approximately one to two hours after administration.

Q: How long does the effect of Cibalgina Dol usually last?

A: The duration of the medicine's effect for symptom relief is generally reflected in the recommended dosing interval. Official sources commonly advise waiting four to six hours between successive doses to maintain an appropriate level of the medicine in the system.

Q: Does Cibalgina Dol interact with common cold medicines?

A: A primary caution in regulatory labeling is to avoid using this medicine with any other product that contains an NSAID. This includes many multi-symptom cold and flu combinations, as using two NSAIDs increases the risk of side effects. Regulatory guidance emphasizes the importance of checking all active ingredients to avoid combining medicines that contain NSAIDs.

Q: Is Cibalgina Dol known to cause drowsiness?

A: Drowsiness is listed in the official product information as a possible adverse effect. This effect can be increased when combined with alcohol or sedatives. Regulatory documents describe that caution is required when driving or operating machinery if drowsiness is experienced.

Q: Is there a risk of developing a dependency on Cibalgina Dol?

A: Ibuprofen is not classified as a controlled substance by major regulatory bodies and is not associated with the addiction or dependency potential of opioid medications. This distinction is based on the substance's pharmacological profile and official legal classification.

Q: Are there any specific instructions for stopping the use of Cibalgina Dol?

A: When the medicine is being used for self-managed acute pain, there are typically no specific instructions for stopping use; the medicine can simply be stopped once the pain is resolved. Official guidance for short-term use does not typically require a tapering of the dose.

Q: Can Cibalgina Dol interact with supplements like St. John's Wort?

A: Official regulatory agencies describe the need for caution when combining any medicine with herbal products such as St. John's Wort. St. John’s Wort is known to potentially affect the liver enzymes that metabolize drugs, which could alter how other medicines work in the body.

Q: Are there known interactions between Cibalgina Dol and medications for diabetes?

A: Official documentation notes that patients with pre-existing conditions like diabetes require careful consideration due to related cardiovascular risks. While a direct drug-drug interaction is not universally listed, caution is advised by regulatory authorities when NSAIDs are used in the context of underlying chronic health conditions.

Q: What are the signs of an allergic reaction to Cibalgina Dol?

A: Regulatory documents include a severe allergic reaction (hypersensitivity) as a serious safety concern. Signs may include hives, facial swelling, asthma (wheezing), shock, or severe skin reactions such as blistering. Official documentation notes that if signs of a severe allergic reaction occur, the medicine should be stopped and immediate medical attention is described as necessary.

Q: Does Cibalgina Dol contain lactose or gluten?

A: The presence of inactive ingredients, or excipients, such as lactose or gluten, depends on the specific formulation (e.g., tablet, capsule, or granule). This exact list of excipients for a particular product is detailed in the official regulatory documentation for that medicine.

Q: Can Cibalgina Dol be taken simultaneously with paracetamol?

A: Regulatory warnings typically focus on avoiding combination with other NSAIDs. There is generally no contraindication to taking ibuprofen (the active ingredient in Cibalgina Dol) with paracetamol (acetaminophen) at recommended doses, as they are different classes of pain relievers. Regulatory information suggests that combined use of different pain relievers should be conducted under the review of a healthcare professional.

Q: Can Cibalgina Dol cause sensitivity to sunlight?

A: Ibuprofen, like other NSAIDs, has occasionally been associated with photosensitivity, which means an increased sensitivity to sunlight or UV light. Some regulatory resources advise that patients use sun protection while taking this type of medication, especially during prolonged sun exposure.

Storage Requirements and Temperature Control

Cibalgina Dol (Ibuprofen 400 mg) should generally be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F) for bottled products. Storage must be below 30 C and the product must be protected from moisture. All forms must be kept in the original container to maintain their integrity and shelf-life, which is often labeled for up to three or four years from the date of manufacture.

Child Safety and Disposal

The most important safety requirement is to keep all medicines out of the sight and reach of children.

Disposal of any unused or expired product must follow local requirements. If drug take-back programs are unavailable, the medicine should not be flushed. Instead, the tablets should be removed from the container, mixed with an undesirable substance like coffee grounds or cat litter, sealed in a bag, and then placed in the household trash, as per official guidelines.